Alimera Sciences, Inc. (ALIM) Tops Q4 EPS by 3c

Alimera Sciences, Inc. (NASDAQ: ALIM) reported Q4 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22).

Sees iluvien EU marketing approval by end of Q1, sees meeting with FDA on iluvien during Q2.

For earnings history and earnings-related data on Alimera Sciences, Inc. (ALIM) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c